Dyax Corp.

+$0.00 (+0.0%)
Closing price January 25, 2016
Last week, a few biotech companies made absolutely massive runs, while others had serious falls.
Shire and Dyax announced Monday morning that former will acquire latter for almost $6 billion.
A report on Wednesday from Janney Capital Markets has targeted several iotech bcompanies it believes are now grossly oversold.
Dyax announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending DX-2930.
The dog days of August have typically meant slow volumes, but it did not keep technology and financial services insiders from unloading shares.
Dyax announced on Tuesday that the FDA has granted a key breakthrough therapy designation for the investigation of DX-2930 for hereditary angioedema .
Monday's top analyst upgrades, downgrades and initiations include AOL, Cisco Systems, Etsy, GoDaddy, MannKind, Virtu Financial, Caterpillar and Nokia.
The newest hot stock in biotechnology is now giving everyone the chance to get a piece of it via an offering of 7 million shares of its common stock.
So far, analysts have not backed off their bullish views of Dyax. In fact, many analysts boosted their price targets remarkably on the news.
Wednesday's top analyst upgrades and downgrades include Alibaba, Altera, Dyax, Hewlett-Packard, Kinder Morgan, Michael Kors, Staples and Twitter.
Dyax is almost certain to dominate the biotech news flow on Wednesday, after it announced positive trial data on Tuesday evening.
A new research report from the analysts at Merrill Lynch includes some timely additions to the firm's SMID-Cap Alpha list.
In a new report from RBC, while they think the selling and profit taking in biotechs could go on, they also hold fast that industry fundamentals are still very positive.
Here are five stocks on the Merrill Lynch SMID-Cap Alpha list that have some big news and events that may be right around the corner. All are rated Buy at Merrill Lynch.
A new research note from Cowen focuses on health care companies that have released earnings and offer investors reasons to own the stocks.